Urothelial Carcinoma
Cabozantinib plus atezolizumab shows potential in advanced urothelial carcinoma
Nivolumab-ipilimumab combination fails to extend OS in urothelial carcinoma subset
Nivolumab plus ipilimumab failed to extend OS compared with standard first-line chemotherapy for patients with unresctable or metastatic urothelial carcinoma whose tumor cells expressed PD-L1 at 1% or greater.
Immune-related adverse events after inhibitor use linked to benefit in urothelial cancer
Patients with urothelial carcinoma who experienced an immune-related adverse event following checkpoint blockade had significantly improved clinical outcomes, according to a poster presented at ASCO Genitourinary Cancers Symposium.
Niraparib regimen fails to improve PFS among subset of patients with urothelial carcinoma
Benefit-risk ratio of lenvatinib plus pembrolizumab not positive in bladder cancer subset
SAN FRANCISCO — Lenvatinib plus pembrolizumab did not demonstrate a positive benefit-risk ratio compared with pembrolizumab and placebo as first-line therapy for certain patients with advanced urothelial carcinoma, study results showed.
Combination active in HER2-expressing urothelial carcinoma
SAN FRANCISCO — The combination of fam-trastuzumab deruxtecan-nxki and nivolumab demonstrated antitumor activity among patients with HER2-expressing urothelial carcinoma, according to results presented at ASCO Genitourinary Cancers Symposium.
FDA grants full approval to Keytruda for urothelial carcinoma subset
The FDA granted full approval to pembrolizumab for first-line treatment of certain patients with advanced urothelial carcinoma, according to the agent’s manufacturer.
FDA approves Opdivo as adjuvant treatment of high-risk urothelial carcinoma
The FDA approved nivolumab for adjuvant treatment of patients with surgically resected, high-risk urothelial carcinoma, according to the agent’s manufacturer.
FDA approves enfortumab vedotin for locally advanced, metastatic urothelial carcinoma
FDA grants priority review to Opdivo as adjuvant treatment of urothelial carcinoma
The FDA granted priority review to nivolumab for adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma, according to the agent’s manufacturer.